ValeurQ4, 24Q4, 25Q1, 26Total du passif—11.38 M13.29 MTotal des capitaux propres—-3.8 M-5.13 MTotal du passif et des capitaux propres—7.58 M8.16 MDette totale———Dette nette———
Oncolytics Biotech Inc. - Common Stock
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.